N-(5-benzamido-1-phenyl-1,2,4-triazol-3-yl)benzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-(5-benzamido-1-phenyl-1,2,4-triazol-3-yl)benzamide
• 化学式: C₂₂H₁₇N₅O₂
• 分子量: 383.4
• InChiKey: GFQQPQUENQSFFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  88.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME
  申请人：An2H Discovery Limited

  公开号：US20200172497A1

  公开（公告）日：2020-06-04

  The present disclosure is directed to asymmetric triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R 1 , R 2 , R 3 , M 1 , M 2 , M 3 , L 1 , L 2 , and L 3 are as defined herein.

  本公开涉及公式（I）和公式（II）的不对称三唑苯甲酰胺化合物，以及其制药组合物和调节或激活Parkin连接酶的方法。本公开还涉及治疗和/或减少与激活Parkin连接酶相关的疾病或症状的方法。R1、R2、R3、M1、M2、M3、L1、L2和L3如本文所定义。
• [EN] TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME<br/>[FR] DÉRIVÉS DE TRIAZOLE BENZAMIDE ET COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT ASSOCIÉS
  申请人：AN2H DISCOVERY LTD

  公开号：WO2017210694A1

  公开（公告）日：2017-12-07

  The present disclosure is directed to triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.

  本公开涉及式(I)和式(II)的三唑苯甲酰胺化合物，以及其药物组合物和调节或激活Parkin连接酶的方法。本公开还涉及治疗和/或减少与激活Parkin连接酶相关的疾病或症状的方法。R1、R2、R3、M1、M2、M3、L1、L2和L3如本文所定义。
• Parkin ligase activation methods and compositions
  申请人：An2H Discovery Limited

  公开号：US10155936B2

  公开（公告）日：2018-12-18

  The present invention is directed to methods and compositions for activating a Parkin ligase by administering to a subject in need thereof a therapeutically effective amount of a compound that disrupts at least one Parkin ligase zinc finger. The present invention is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase.

  本发明涉及通过向有需要的受试者施用治疗有效量的破坏至少一个Parkin连接酶锌指的化合物来激活Parkin连接酶的方法和组合物。本发明还涉及治疗和/或降低与激活Parkin连接酶有关的疾病或病症发病率的方法。
• Triazole benzamide derivatives and the compositions and methods of treatment regarding the same
  申请人：An2H Discovery Limited

  公开号：US10308617B2

  公开（公告）日：2019-06-04

  The present disclosure is directed to triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.

  本公开涉及式(I)和式(II)的三唑苯甲酰胺化合物、其药物组合物以及调节或激活Parkin连接酶的方法。本公开还涉及治疗和/或减少与激活Parkin连接酶有关的疾病或病症的方法。R1、R2、R3、M1、M2、M3、L1、L2 和 L3 如本文所定义。
• Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same
  申请人：NysnoBio Ireland DAC

  公开号：US10889553B2

  公开（公告）日：2021-01-12

  The present disclosure is directed to asymmetric triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.

  本公开涉及式(I)和式(II)的不对称三唑苯甲酰胺化合物、其药物组合物以及调节或激活Parkin连接酶的方法。本公开还涉及治疗和/或降低与激活Parkin连接酶有关的疾病或病症发病率的方法。R1、R2、R3、M1、M2、M3、L1、L2 和 L3 如本文所定义。